Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HNRNPA2B1

Gene summary for HNRNPA2B1

Gene summary.

Gene information	Species	Human
	Gene symbol	HNRNPA2B1
	Gene ID	3181
	Gene name	heterogeneous nuclear ribonucleoprotein A2/B1
	Gene Alias	HNRNPA2
	Cytomap	7p15.2
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	P22626

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3181	HNRNPA2B1	GSM5353222_PA_PB2B_Pool_1_3_S52_L002	Human	Prostate	Tumor	1.28e-16	2.49e-01	0.1608
3181	HNRNPA2B1	GSM5353223_PA_PB2B_Pool_2_S26_L001	Human	Prostate	Tumor	1.90e-13	3.06e-01	0.1604
3181	HNRNPA2B1	GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001	Human	Prostate	Tumor	6.48e-05	3.17e-01	0.1621
3181	HNRNPA2B1	GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002	Human	Prostate	Tumor	1.80e-02	2.28e-01	0.1619
3181	HNRNPA2B1	GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002	Human	Prostate	Tumor	2.02e-09	1.93e-01	0.1602
3181	HNRNPA2B1	GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004	Human	Prostate	Tumor	7.46e-03	-3.78e-01	0.1537
3181	HNRNPA2B1	GSM5353232_PA_PR5249_T1_S3_L001	Human	Prostate	Tumor	1.01e-03	-4.36e-01	0.1439
3181	HNRNPA2B1	GSM5353236_PA_PR5251_T1_S7_L001	Human	Prostate	Tumor	1.82e-11	3.22e-01	0.1608
3181	HNRNPA2B1	GSM5353237_PA_PR5251_T2_S8_L001	Human	Prostate	Tumor	7.53e-05	3.36e-01	0.1622
3181	HNRNPA2B1	GSM5353240_PA_PR5254_T1_S15_L001	Human	Prostate	Tumor	1.44e-17	8.25e-02	0.1575
3181	HNRNPA2B1	GSM5353243_PA_PR5261_T1_S23_L002	Human	Prostate	Tumor	4.49e-45	1.47e-01	0.1545
3181	HNRNPA2B1	GSM5353244_PA_PR5261_T2_S24_L002	Human	Prostate	Tumor	2.01e-28	4.35e-02	0.1569
3181	HNRNPA2B1	GSM5353247_PA_PR5269_3_S27_L002	Human	Prostate	Tumor	4.88e-04	-2.87e-02	0.1532
3181	HNRNPA2B1	GSM5353248_PA_PR5269_4_S28_L002	Human	Prostate	Tumor	7.02e-09	1.46e-01	0.1541
3181	HNRNPA2B1	P1_S1_AK	Human	Skin	AK	2.44e-05	2.31e-01	-0.3399
3181	HNRNPA2B1	P4_S8_cSCC	Human	Skin	cSCC	1.69e-08	2.33e-02	-0.3095
3181	HNRNPA2B1	P5_S10_cSCC	Human	Skin	cSCC	4.66e-19	3.21e-01	-0.299
3181	HNRNPA2B1	P1_cSCC	Human	Skin	cSCC	6.56e-56	2.50e+00	0.0292
3181	HNRNPA2B1	P2_cSCC	Human	Skin	cSCC	3.53e-51	2.10e+00	-0.024
3181	HNRNPA2B1	P4_cSCC	Human	Skin	cSCC	2.18e-59	2.12e+00	-0.00290000000000005

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00083809	Breast	Precancer	RNA splicing	65/1080	434/18723	1.27e-12	2.53e-10	65
GO:00003759	Breast	Precancer	RNA splicing, via transesterification reactions	52/1080	324/18723	1.74e-11	2.22e-09	52
GO:00003779	Breast	Precancer	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00003989	Breast	Precancer	mRNA splicing, via spliceosome	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00108338	Breast	Precancer	telomere maintenance via telomere lengthening	15/1080	81/18723	5.31e-05	1.11e-03	15
GO:00007238	Breast	Precancer	telomere maintenance	20/1080	131/18723	6.10e-05	1.25e-03	20
GO:00344705	Breast	Precancer	ncRNA processing	42/1080	395/18723	9.91e-05	1.83e-03	42
GO:19043567	Breast	Precancer	regulation of telomere maintenance via telomere lengthening	12/1080	61/18723	1.61e-04	2.69e-03	12
GO:19043588	Breast	Precancer	positive regulation of telomere maintenance via telomere lengthening	9/1080	37/18723	1.96e-04	3.10e-03	9
GO:20002788	Breast	Precancer	regulation of DNA biosynthetic process	16/1080	106/18723	3.68e-04	5.03e-03	16
GO:00322047	Breast	Precancer	regulation of telomere maintenance	13/1080	80/18723	6.23e-04	7.78e-03	13
GO:00322003	Breast	Precancer	telomere organization	20/1080	159/18723	8.45e-04	9.82e-03	20
GO:00346604	Breast	Precancer	ncRNA metabolic process	45/1080	485/18723	1.15e-03	1.26e-02	45
GO:00519728	Breast	Precancer	regulation of telomerase activity	9/1080	47/18723	1.28e-03	1.36e-02	9
GO:00064039	Breast	Precancer	RNA localization	23/1080	201/18723	1.34e-03	1.41e-02	23
GO:00510548	Breast	Precancer	positive regulation of DNA metabolic process	23/1080	201/18723	1.34e-03	1.41e-02	23
GO:20012529	Breast	Precancer	positive regulation of chromosome organization	12/1080	82/18723	2.51e-03	2.29e-02	12
GO:00322068	Breast	Precancer	positive regulation of telomere maintenance	9/1080	52/18723	2.67e-03	2.36e-02	9
GO:000838014	Breast	IDC	RNA splicing	73/1434	434/18723	1.27e-10	1.57e-08	73
GO:000037514	Breast	IDC	RNA splicing, via transesterification reactions	58/1434	324/18723	9.44e-10	9.58e-08	58

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501416	Breast	Precancer	Amyotrophic lateral sclerosis	98/684	364/8465	2.13e-28	8.41e-27	6.44e-27	98
hsa0501417	Breast	Precancer	Amyotrophic lateral sclerosis	98/684	364/8465	2.13e-28	8.41e-27	6.44e-27	98
hsa0501423	Breast	IDC	Amyotrophic lateral sclerosis	102/867	364/8465	1.29e-22	5.22e-21	3.91e-21	102
hsa0501433	Breast	IDC	Amyotrophic lateral sclerosis	102/867	364/8465	1.29e-22	5.22e-21	3.91e-21	102
hsa0501443	Breast	DCIS	Amyotrophic lateral sclerosis	101/846	364/8465	7.14e-23	2.88e-21	2.12e-21	101
hsa0501453	Breast	DCIS	Amyotrophic lateral sclerosis	101/846	364/8465	7.14e-23	2.88e-21	2.12e-21	101
hsa05014	Colorectum	AD	Amyotrophic lateral sclerosis	164/2092	364/8465	4.28e-18	1.27e-16	8.09e-17	164
hsa050141	Colorectum	AD	Amyotrophic lateral sclerosis	164/2092	364/8465	4.28e-18	1.27e-16	8.09e-17	164
hsa050142	Colorectum	SER	Amyotrophic lateral sclerosis	138/1580	364/8465	9.89e-19	2.99e-17	2.17e-17	138
hsa050143	Colorectum	SER	Amyotrophic lateral sclerosis	138/1580	364/8465	9.89e-19	2.99e-17	2.17e-17	138
hsa050144	Colorectum	MSS	Amyotrophic lateral sclerosis	156/1875	364/8465	1.43e-19	4.62e-18	2.83e-18	156
hsa050145	Colorectum	MSS	Amyotrophic lateral sclerosis	156/1875	364/8465	1.43e-19	4.62e-18	2.83e-18	156
hsa050146	Colorectum	MSI-H	Amyotrophic lateral sclerosis	95/797	364/8465	2.31e-21	1.50e-19	1.26e-19	95
hsa050147	Colorectum	MSI-H	Amyotrophic lateral sclerosis	95/797	364/8465	2.31e-21	1.50e-19	1.26e-19	95
hsa050148	Colorectum	FAP	Amyotrophic lateral sclerosis	91/1404	364/8465	1.84e-05	2.36e-04	1.44e-04	91
hsa050149	Colorectum	FAP	Amyotrophic lateral sclerosis	91/1404	364/8465	1.84e-05	2.36e-04	1.44e-04	91
hsa0501420	Endometrium	AEH	Amyotrophic lateral sclerosis	123/1197	364/8465	2.17e-22	7.82e-21	5.72e-21	123
hsa05014110	Endometrium	AEH	Amyotrophic lateral sclerosis	123/1197	364/8465	2.17e-22	7.82e-21	5.72e-21	123
hsa0501425	Endometrium	EEC	Amyotrophic lateral sclerosis	128/1237	364/8465	9.83e-24	4.04e-22	3.01e-22	128
hsa0501435	Endometrium	EEC	Amyotrophic lateral sclerosis	128/1237	364/8465	9.83e-24	4.04e-22	3.01e-22	128

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HNRNPA2B1

SNV

Missense_Mutation

c.951N>C

p.Lys317Asn

p.K317N

P22626

protein_coding

deleterious(0.03)

benign(0.264)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HNRNPA2B1

SNV

Missense_Mutation

c.209N>T

p.Ser70Leu

p.S70L

P22626

protein_coding

deleterious(0.03)

probably_damaging(0.975)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HNRNPA2B1

SNV

Missense_Mutation

c.124G>C

p.Glu42Gln

p.E42Q

P22626

protein_coding

tolerated(0.13)

benign(0.192)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

HNRNPA2B1

SNV

Missense_Mutation

c.46N>A

p.Glu16Lys

p.E16K

P22626

protein_coding

deleterious(0.01)

probably_damaging(0.932)

TCGA-GM-A2D9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

HNRNPA2B1

SNV

Missense_Mutation

novel

c.869A>G

p.Tyr290Cys

p.Y290C

P22626

protein_coding

tolerated(0.17)

benign(0.339)

TCGA-OL-A5RW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

HNRNPA2B1

SNV

Missense_Mutation

novel

c.353G>A

p.Gly118Glu

p.G118E

P22626

protein_coding

deleterious(0.01)

probably_damaging(0.954)

TCGA-HM-A4S6-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

HNRNPA2B1

insertion

In_Frame_Ins

novel

c.356_357insGAACAAAAA

p.Ile119delinsMetAsnLysAsn

p.I119delinsMNKN

P22626

protein_coding

TCGA-DS-A1OC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

gemcitabine

HNRNPA2B1

SNV

Missense_Mutation

c.185N>T

p.Arg62Ile

p.R62I

P22626

protein_coding

deleterious(0.01)

probably_damaging(0.975)

TCGA-AA-A010-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Chemotherapy

folinic

HNRNPA2B1

SNV

Missense_Mutation

c.565N>C

p.Ser189Pro

p.S189P

P22626

protein_coding

tolerated(0.08)

probably_damaging(0.927)

TCGA-G4-6628-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

HNRNPA2B1

SNV

Missense_Mutation

novel

c.389A>C

p.Asp130Ala

p.D130A

P22626

protein_coding

deleterious(0)

possibly_damaging(0.467)

TCGA-A5-A0G1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1